Plitidepsin

CHEMBL451930 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1110.3 g/mol

LogP

5.7

Phase

4

Plitidepsin is a cyclic depsipeptide of marine origin derived from the tunicate Aplidium albicans that exerts anticancer activity by inhibiting protein synthesis through binding to eukaryotic elongation factor 1A2 (eEF1A2), disrupting the elongation phase of translation. It has demonstrated activity in multiple myeloma, T-cell lymphoma, and leukemia, and has also shown antiviral activity against SARS-CoV-2.

Masse moléculaire

1110,3000 g/mol

LogP

5,70

TPSA

285,00 Å²

Règle des 5 de Lipinski

Non conforme

Aires thérapeutiques

Lymphoma Prostate Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CC[C@H](C)[C@H]1NC(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H]2CCCN2C(=O)C(C)=O)[C@@H](C)OC(=O)[C@H](Cc2ccc(OC)cc2)N(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)C(=O)[C@H](C(C)C)OC(=O)C[C@@H]1O

InChI

InChI=1S/C57H87N7O15/c1-15-33(8)46-44(66)29-45(67)79-49(32(6)7)48(68)34(9)50(69)58-39(26-30(2)3)54(73)64-25-17-19-41(64)56(75)62(13)43(28-37-20-22-38(77-14)23-21-37)57(76)78-36(11)47(52(71)59-46)60-51(70)42(27-31(4)5)61(12)55(74)40-18-16-24-63(40)53(72)35(10)65/h20-23,30-34,36,39-44,46-47,49,66H,15-19,24-29H2,1-14H3,(H,58,69)(H,59,71)(H,60,70)/t33-,34-,36+,39-,40-,41-,42+,43-,44-,46+,47-,49-/m0/s1

Molecular Formula

C57H87N7O15

HBD / HBA

4 / 15

Liaisons Rotatives

15

Atomes Lourds

79

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

Plitidepsin is a cyclic depsipeptide of marine origin derived from the tunicate Aplidium albicans that exerts anticancer activity by inhibiting protein synthesis through binding to eukaryotic elongation factor 1A2 (eEF1A2), disrupting the elongation phase of translation. It has demonstrated activity in multiple myeloma, T-cell lymphoma, and leukemia, and has also shown antiviral activity against SARS-CoV-2.

Yes, Plitidepsin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL451930. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 9812534. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Plitidepsin sur PillFYI

Structure

Données Clés

Formule: C57H87N7O15

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.